Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03229083 · ClinicalTrials.gov registry record · NA
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03229083 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 21 participants.
The verdict
NCT03229083, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.
Interventions
- OTHER Carevive software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-24 |
| Est. Completion | 2025-02-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03229083
The ClinicalTrials.gov registry entry for NCT03229083 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carevive software is the first listed.
NCT03229083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03229083 about?
NCT03229083 is a clinical study titled "Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma". To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-relat...
What is the current status of trial NCT03229083?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2019-07-24. Estimated completion is 2025-02-14.
What interventions are being tested in trial NCT03229083?
The interventions under investigation include: Carevive software (OTHER).
Who is sponsoring clinical trial NCT03229083?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.